Known targets — ChEMBL curated mechanism
GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ
The experimentally established mechanism targets of Lorazepam. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 known ✓ | P14867 | 8/20 | 0.63 |
| ▸ | GABRA5 known ✓ | P31644 | 8/20 | 0.63 |
| ▸ | GABRA2 known ✓ | P47869 | 8/20 | 0.63 |
| ▸ | GABRB2 known ✓ | P47870 | 7/20 | 0.63 |
| ▸ | GABRG2 known ✓ | P18507 | 7/20 | 0.63 |
| ▸ | GABRB3 known ✓ | P28472 | 7/20 | 0.63 |
| ▸ | GABRA3 known ✓ | P34903 | 7/20 | 0.63 |
| ▸ | GABRP known ✓ | O00591 | 3/20 | 0.63 |
| ▸ | GABRD known ✓ | O14764 | 3/20 | 0.63 |
| ▸ | GABRB1 known ✓ | P18505 | 3/20 | 0.63 |
| ▸ | GABRA4 known ✓ | P48169 | 3/20 | 0.63 |
| ▸ | GABRE known ✓ | P78334 | 3/20 | 0.63 |
| ▸ | GABRA6 known ✓ | Q16445 | 3/20 | 0.63 |
| ▸ | GABRG1 known ✓ | Q8N1C3 | 3/20 | 0.63 |
| ▸ | GABRG3 known ✓ | Q99928 | 3/20 | 0.63 |
| ▸ | GABRQ known ✓ | Q9UN88 | 3/20 | 0.63 |
| ▸ | LMNA | P02545 | 4/20 | 0.65 |
| ▸ | PGR | P06401 | 1/20 | 0.65 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.63 |
| ▸ | ALB | P02768 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diazepam SCHEMBL10948878 | 0.94 | GABRA1 (0.69) | LMNAPGRGABRA1GABRA5GABRA2 | |
| Halazepam SCHEMBL8319463 | 0.91 | OPRK1 (0.61) | LMNAPGRGABRA1GABRA5GABRA2 | |
| Lorazepam SCHEMBL4978513 | 0.87 | ADRA1A (0.51) | LMNAPGRGABRA1GABRA5GABRA2 | |
| Halazepam SCHEMBL7624840 | 0.86 | OPRK1 (0.68) | LMNAPGRGABRA1GABRA5GABRA2 | |
| Diazepam SCHEMBL1003950 | 0.86 | GABRA1 (0.70) | LMNAGABRA1GABRA5GABRA2GABRB2 | |
| Alprazolam SCHEMBL19816867 | 0.85 | GABRA1 (0.63) | LMNAPGRGABRA1GABRA5GABRA2 | |
| Flunitrazepam SCHEMBL18316507 | 0.84 | GABRA1 (0.63) | LMNAPGRGABRA1GABRA5GABRA2 | |
| Lorazepam SCHEMBL3695725 | 0.84 | LMNA (0.89) | LMNAPGRGABRA1GABRA5GABRA2 | |
| Temazepam SCHEMBL7036032 | 0.83 | OPRK1 (0.82) | LMNAGABRA1GABRA5GABRA2GABRB2 | |
| Clobazam SCHEMBL21244067 | 0.83 | LMNA (0.64) | LMNAPGRGABRA1GABRA5GABRA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230080958-A1 | METHODS OF TREATING PSEUDOBULBAR AFFECT AND OTHER EMOTIONAL DISTURBANCES | WOOLSEY PHARMACEUTICALS, INC. | 2023-03-16 | — | — | US | disclosed |
| EP-4103187-A1 | METHODS OF TREATING PSEUDOBULBAR AFFECT AND OTHER EMOTIONAL DISTURBANCES | Woolsey Pharmaceuticals, Inc. (US) | 2022-12-21 | — | — | EP | disclosed |
| WO-2021162808-A1 | METHODS OF TREATING PSEUDOBULBAR AFFECT AND OTHER EMOTIONAL DISTURBANCES | WOOLSEY PHARMACEUTICALS, INC (US) | 2021-08-19 | — | — | WO | disclosed |
| EP-1633366-A4 | PHARMACEUTICAL COMPOSITION BASED ON AGONIST OF BENZODIAZEPINE | SIGMA PHARMA LTDA (BR) | 2008-02-27 | — | — | EP | disclosed |
| EP-1633366-A1 | PHARMACEUTICAL COMPOSITION BASED ON AGONIST OF BENZODIAZEPINE | Sigma Pharma Ltda. (BR) | 2006-03-15 | — | — | EP | disclosed |
| WO-2004105767-A1 | PHARMACEUTICAL COMPOSITION BASED ON AGONIST OF BENZODIAZEPINE | SIGMA PHARMA LTDA. (BR) | 2004-12-09 | — | — | WO | disclosed |
| US-5449682-A | Angiotensin II antagonists incorporating a substituted benzyl element | MERCK & CO., INC. (US) | 1995-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230080958-A1 | METHODS OF TREATING PSEUDOBULBAR AFFECT AND OTHER EMOTIONAL DISTURBANCES | ROCK2, MAPT, ROCK1 | GABRA1 579/4885GABRA5 383/4885GABRA2 541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.